# FDA 483 - AstraZeneca Pharmaceuticals LP - June 07, 2024

Source: https://www.globalkeysolutions.net/records/483/astrazeneca-pharmaceuticals-lp/6809d725-a3ed-4b2b-b0a2-b81cc7e01672

> FDA 483 for AstraZeneca Pharmaceuticals LP on June 07, 2024. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: AstraZeneca Pharmaceuticals LP
- Inspection Date: 2024-06-07
- Product Type: drugs
- Office Name: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)

## Related Documents

- [WARNING_LETTER - 2023-08-15](https://www.globalkeysolutions.net/records/warning_letter/astrazeneca-pharmaceuticals-lp/ffb41aa4-e9b4-4e4e-b72f-9cf78acb857c)
- [483 - Unknown Date](https://www.globalkeysolutions.net/records/483/astrazeneca-pharmaceuticals-lp/18be36a6-b748-456a-9e2b-93a50fc65442)
- [483 - 2023-01-19](https://www.globalkeysolutions.net/records/483/astrazeneca-pharmaceuticals-lp/478db057-80d8-4a2c-947c-22026c39adb6)
- [EIR - Unknown Date](https://www.globalkeysolutions.net/records/eir/astrazeneca-pharmaceuticals-lp/3d033ebe-b0ca-4656-8ab5-10333ded858b)
- [483 - 2024-06-07](https://www.globalkeysolutions.net/records/483/astrazeneca-pharmaceuticals-lp/f295582f-0d0d-456b-8a87-9c3c9acec931)

## Related Officers

- [Liqun Zhao](https://www.globalkeysolutions.net/people/liqun-zhao/6fdfb753-7788-4351-9b0b-65e06c201bc5)
- [Vidya B. Pai](https://www.globalkeysolutions.net/people/vidya-b-pai/bbe3989c-b7b0-40a0-ae0b-a35c81cdd179)
- [Christina Farris](https://www.globalkeysolutions.net/people/christina-farris/cf4c3a4d-bf6e-424a-9e7d-f5dd32e41769)
- [Kristen Nickens](https://www.globalkeysolutions.net/people/kristen-nickens/d68c87e1-e14c-48f7-86e9-686a3870c777)
- [Senior Regulatory Specialist](https://www.globalkeysolutions.net/people/wayne-e-seifert/e92e1f10-c61e-4b08-9156-25907e5e2942)

Company: https://www.globalkeysolutions.net/companies/astrazeneca-pharmaceuticals-lp/6f9abb75-9352-43df-b761-026089396fa3

Office: https://www.globalkeysolutions.net/offices/division-of-clinical-evidence-and-analysis-1-clinical-policy-and-quality/5f95da17-30bb-423f-b892-5ea041823fbd